Compare with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON ALKEM LABORATORIES/
BIOCON
 
P/E (TTM) x 24.5 30.5 80.2% View Chart
P/BV x 5.9 3.9 152.7% View Chart
Dividend Yield % 0.8 0.3 323.0%  

Financials

 ALKEM LABORATORIES   BIOCON
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
BIOCON
Mar-19
ALKEM LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs2,720707 384.6%   
Low Rs1,660554 299.8%   
Sales per share (Unadj.) Rs697.991.9 759.3%  
Earnings per share (Unadj.) Rs96.116.7 575.2%  
Cash flow per share (Unadj.) Rs117.324.2 485.1%  
Dividends per share (Unadj.) Rs25.001.00 2,500.0%  
Dividend yield (eoy) %1.10.2 719.7%  
Book value per share (Unadj.) Rs515.2101.6 507.0%  
Shares outstanding (eoy) m119.57600.00 19.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.16.9 45.7%   
Avg P/E ratio x22.837.7 60.4%  
P/CF ratio (eoy) x18.726.1 71.6%  
Price / Book Value ratio x4.36.2 68.5%  
Dividend payout %26.06.0 434.6%   
Avg Mkt Cap Rs m261,879378,330 69.2%   
No. of employees `00014.36.1 233.7%   
Total wages/salary Rs m15,05511,653 129.2%   
Avg. sales/employee Rs Th5,822.68,994.3 64.7%   
Avg. wages/employee Rs Th1,050.51,900.7 55.3%   
Avg. net profit/employee Rs Th802.01,635.3 49.0%   
INCOME DATA
Net Sales Rs m83,44455,144 151.3%  
Other income Rs m1,0421,444 72.2%   
Total revenues Rs m84,48656,588 149.3%   
Gross profit Rs m14,73415,883 92.8%  
Depreciation Rs m2,5284,478 56.4%   
Interest Rs m651709 91.8%   
Profit before tax Rs m12,59812,140 103.8%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1052,123 52.0%   
Profit after tax Rs m11,49310,026 114.6%  
Gross profit margin %17.728.8 61.3%  
Effective tax rate %8.817.5 50.1%   
Net profit margin %13.818.2 75.8%  
BALANCE SHEET DATA
Current assets Rs m54,96048,228 114.0%   
Current liabilities Rs m32,43330,376 106.8%   
Net working cap to sales %27.032.4 83.4%  
Current ratio x1.71.6 106.7%  
Inventory Days Days8068 116.5%  
Debtors Days Days7286 84.4%  
Net fixed assets Rs m32,71064,130 51.0%   
Share capital Rs m2393,000 8.0%   
"Free" reserves Rs m61,36857,980 105.8%   
Net worth Rs m61,60760,980 101.0%   
Long term debt Rs m1,59215,766 10.1%   
Total assets Rs m99,433121,924 81.6%  
Interest coverage x20.418.1 112.4%   
Debt to equity ratio x00.3 10.0%  
Sales to assets ratio x0.80.5 185.5%   
Return on assets %12.28.8 138.7%  
Return on equity %18.716.4 113.5%  
Return on capital %21.016.8 125.1%  
Exports to sales %19.128.1 67.8%   
Imports to sales %3.018.9 15.8%   
Exports (fob) Rs m15,91715,506 102.7%   
Imports (cif) Rs m2,48310,399 23.9%   
Fx inflow Rs m16,06115,506 103.6%   
Fx outflow Rs m2,48310,399 23.9%   
Net fx Rs m13,5785,107 265.9%   
CASH FLOW
From Operations Rs m5,85111,546 50.7%  
From Investments Rs m-7,414-7,138 103.9%  
From Financial Activity Rs m792-2,417 -32.7%  
Net Cashflow Rs m-7312,103 -34.8%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC  NATCO PHARMA  CADILA HEALTHCARE  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

BIOCON Share Price Down by 10%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).

SRF Share Price Down by 5%; BSE 500 Index Up 0.3% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

SRF share price is trading down by 5% and its current market price is Rs 5,715. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are JK TYRE & IND (up 14.5%) and CYIENT (up 11.1%). The top losers are SRF (down 5.1%) and BIOCON (down 8.7%).

BIOCON Share Price Down by 6%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2021 03:36 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS